Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 27, Issue 5-6, 1997, Pages 523-532

  Knauf, W U ^a   Langenmayer, I ^b   Ehlers, B ^a   Mohr, B ^a   Adorf, D ^c   Nerl, C H ^c   Hallek, M ^b   Zwingers, T H ^d   Emmerich, B ^b   Thiel, E ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c O   (Germany)

^d Estimate Statistics Inc Augsburg   (Germany)

Author keywords

Chronic lymphocytic leukemia; Disease progression; Early stage; Risk factors; Soluble CD23

Indexed keywords

CD23 ANTIGEN; INTERLEUKIN 2 RECEPTOR; THYMIDINE KINASE;

ARTICLE; B CELL LEUKEMIA; BONE MARROW; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL;

EID: 6844261185     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058320     Document Type: Article

References (54)

1. Foon, K. A., Rai, K. R. and Gale, R. P. (1990). Chronic lymphocytic leukemia: New insights into biology and therapy. Ann. Int. Med., 113, 525-539.
2. Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N. and Pasternak, B. S. (1975). Clinical staging of chronic lymphocytic leukemia. Blood, 46, 219-234.
3. Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberlin, F., Thomas, M., Tchernia, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M. T., Monconduit, M., Belabbes, S. and Gremy, F. (1981). A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, 198-206.
4. Montserrat, E., Vinolas, N., Reverter, J. C. and Rozman, C. (1988). Natural history of chronic lymphocytic leukemia: On the progression and prognosis of early clinical stages. Nouv. Rev. Fr. Hematol., 30, 359-361.
5. Rozman, C., Montserrat, E., Rodriguez-Fernandez, J. M., Ayats, R., Vallespi, T., Parody, R., Rios, A., Prados, D., Morey, M., Gomis, F., Alcala, A., Guiterrez, M., Maldonado, J., Gonzalez, C., Giralt, M., Hernandez-Nieto, L., Cabrera, A. and Fernandez-Rananda, J. M. (1984). Bone marrow histologic pattern: The best single prognostic parameter in chronic lymphocytic leukemia. A multivariate analysis of 329 cases. Blood, 64, 642-648.
6. Montserrat, E., Sanchez-Bisono, J., Vinolas, N. and Rozman, C. (1986). Lymphocyte doubling time in chronic Iymphocytic leukemia: Analysis of its prognostic significance. Brit. J. Haematol., 62, 567-575.
7. Källander, C., Simonsson, B., Hagberg, B. and Gronowitz, J. (1984). Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer, 54, 2450-2455.
8. 2-microglobulin in chronic lymphocytic leukemia. Scand. J. Haematol., 24, 174-180.
9. Juliusson, G., Oscier, D. G., Fitchett, M., Ross, F. M., Stockdill, G., Mackie, M. J., Parker, A. C., Castoldi, G. L., Cuneo, A., Knuutila, S., Elonen, E. and Gahrton, G. (1990). Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N. Engl. J. Med., 323, 720-724.
10. Bernstein, Z. P., Fitzpatrick, J. E., O'Donnell, A., Han, T., Foon, K. A. and Bhargava, A. (1992). Clinical significance of monoclonal proteins in chronic lymphocylic leukemia. Leukemia, 6, 1243-1245.
11. Semenzato, G., Siviero, F., Vinante, F., Zambello, R., Trentin, L., Agostini, C., Adami, F., Vincenzi, C., Zanotti, R., Zuppini, B., Chilosi, M. and Pizzolo, G. (1989). Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. Eur. J. Cancer Clin. Oncol., 25, 1577-1581.
12. Sarfati, M., Bron, D., Lagneaux, L., Fonleyn, C., Frost, H. and Delespesse, G. (1988). Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood, 71, 94-98.
13. Semenzato, G., Foa, R., Agostini, C., Zambelli, R., Trentin, L., Vinante, F., Benedetti, F., Chilosi, M. and Pizzolo, G. (1987). High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood, 70, 396-400.
14. van Oer's, M. H. J., Pals, S. T., Evers, L. M., van der School, C. E., Koopman, G. and van Lier, R. A. W. (1993). Expression and release of CD27 in human B-cell malignancies. Blood, 82, 3430-3436.
15. Christiansen, I., Gidlöf, C., Wallgren, A., Simonsson, B. and Töttermann, T. H. (1994). Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic parameters. Blood, 84, 3010-3016.
16. Delespesse, G., Suter, U., Mossolayi, D., Bettler, B., Sarfati, M., Hofstetter, H., Kilcherr, E., Debre, P. and Dalloul, A. (1991). Expression, structure, and function of the CD23 antigen. Adv. Immunol, 49, 149-191.
17. Yokota, A., Kikutani, H., Tanaka, T., Sato, R., Barsumian, E. L., Suemura, M. and Kishimoto, T. (1988). Two species of human Fc-receptor II (FcR II/CD23): Tissue-specific and IL-4-specific regulation of gene expression. Cell, 55, 611-618.
18. Punnonen, J., Aversa, G., Cocks, B. G., McKenzie, A. N., Menon, S., Zuwarski, G., de Waal Malefyt, R. and de Vries, J. E. (1993). Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B- cells. Proc. Natl. Acad. Sci. USA, 90, 3730-3734.
19. Sarfati, M., Fournier, S., Christoffersen, M. and Biron, G. (1990). Expression of CD23 antigen and its regulation by IL-4 in chronic lymphocytic leukemia. Leukemia Res., 14, 47-55.
20. Foumier, S., Tran, I. D., Suter, U., Biron, G., Delespesse, G. and Sarfati, M. (1991). The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemia is associated with an abnormally low CD23 upregulation by IL-4: comparison with their normal cellular counterparts. Leukemia Res., 15, 609-618.
21. Nakajima, T., Sarfati, M. and Delespesse, G. (1987). Relationship between human IgE-binding factors (IgE-BF) and lymphocyte receptors for IgE. J. ImmunoL, 139, 848-854.
22. Matutes, E., Owusu-Ankomah, K., Morilla, R., Marco, J. G., Houlihan, A., Que, T. H. and Catovsky, D. (1994). The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia, 8, 1640-1645.
23. Uchiyama, T., Broder, T. and Waldmann, T. A. (1981). A monoclonal antibody (anti-Tac) reactive with activated and functionally mature T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac+ cells. J. Immunol., 126, 1393-1397.
24. Tsudo, M., Uchiyama, T. and Uchino, H. (1984). Expression of the Tac antigen on activated normal human B-cells. J. Exp. Med., 160, 612-617.
25. Herrmann, F., Canistra, S. A., Levine, H. and Griffin, J. D. (1985). Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J. Exp. Med., 162, 1111-1116.
26. Jaques, Y., LeMauff, B., Boeffard, F., Godard, A. and Solillou, J. P. (1987). A soluble interleukin 2 receptor produced by a normal alloreactive human T-cell clone binds interleukin 2 with low affinity. J. Immunol., 139, 2308-2316.
27. Rubin, L. A., Kuman, C. C., Fritz, M. E., Biddison, W. E., Boutin, B., Yarchoan, R. and Nelsonm, D. L. (1985). Soluble interleukin-2-receptors are released from activated human lymphoid cells in vitro. J. Immunol., 135, 3172-3177.
28. Scheibenbogen, C., Keilholz, U., Richter, M., Andreesen, R. and Hunstein, W. (1992). The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the and chains (p55 and p75). Res. Immunol., 143, 33-37.
29. Ambrosetti, A., Semenzato, G., Prior, M., Chilosi, M., Vinante, F., Vincenzi, V., Zanotti, R., Trentin, L., Portuese, A., Menestrina, F., Perona, G., Agostini, C., Todeschini, G. and Pizzolo, G. (1989). Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. Brit. J. Haematol., 73, 181-186.
30. Chilosi, M., Semenzato, G., Vinante, F., Menestrina, F., Piazzola, E., Focchiatti, V., Sabbioni, R., Zanotti, R. and Pizzolo, G. (1989). Increased levels of soluble interleukin-2 receptor in Non-Hodgkin's lymphoma. Am. J. Clin. Pathol., 92, 186-191.
31. Pui, C. H., Schell, M. J., Vodian, M. A., Kline, S., Mirro, J., Christ, W. M. and Behm, F. G. (1991). Serum CD4, CD8, and interleukin-2 receptor levels in childhood acute myeloid leukemia. Leukemia, 5, 249-254.
32. Kay, N. E., Burton, J., Wagner, D. and Nelson, D. L. (1988). The malignant B-cells from B-chronic lymphocytic leukemia patients release Tac-soluble interleukin-2 receptors. Blood, 72, 447-450.
33. Gronowitz, J. S., Hagberg, H., Källander, C. F. R. and Simonsson, B. (1980). Optimized assay for thymidine kinase and its application for the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect. Immunol., 29, 425-434.
34. Kaplan, E. L. and Meier, P. (1958). Nonparametric estimation from incomplete observations. J. Am. Statist. Ass., 53, 457-481.
35. Cox, D. (1972). Regression models and life tables (with discussion). J. Royal Statist. Soc., series B, 34, 187-220.
36. Reinisch, W., Willheim, M., Hilgarth, M., Gasche, C., Mader, R., Szepfalusi, S., Steger, G., Berger, R., Lechner, K., Boltz-Nitulescu, G. and Schwarzmeier, J. D. (1994). Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J. Clin. Oncol., 12, 2146-2152.
37. Beguin, Y., Lampertz, S., DeGroote, D., Igot, D., Malaise, M. and Fillet, G. (1993). Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in the serum of patients with chronic lymphocytic leukemia. Leukemia, 7, 2019-2025.
38. Knauf, W. U., Raghavachar, A., Zeigmeister, B., Ludwig, W.-D. and Thiel, E. (1994). Serum levels of sCD8, sCD25, and sCD23 in B-cell chronic lymphocytic leukemia: Correlation with disease activity and tumor load. In: Cytokines in Hemopoiesis, Oncology, and Immunology III, (eds.) M. Freund, H. Link, R. Schmidt and K. Welte, pp 435-436. (Springer Verlag, Berlin-Heidelberg).
39. Musolino, C., Di Cesare, E., Alonci, A., Allebra, A., Orlando, A., Grosso, P. and Squadrito, G. (1991). Serum levels of CD8 antigen and soluble interleukin-2-receptor in patients with B-cell chronic lymphocytic leukemia. Acta Haematol., 85, 57-61.
40. Pangalis, G. A., Roussou, P. A., Kittas, C., Kokkinou, S. and Fessas, P. (1987). B-chronic lymphocytic leukemias. Prognostic implication of bone marrow histology in 120 patients. Experience from a single hematology unit. Cancer, 59, 767-771.
41. Geisler, C. H., Hou-Jensen, K., Myhre Jensen, O., Tingaurd-Pedersen, N., Mork Hansen, M., Hansen, N. E., Holm, M., Egelund Christensen, B., Drivsholm, A., Boye Nielsen, J., Thorling, K., Andersen, E., Larsen, J. K. and Kragh Andersen, P. (1994). The bone marrow infiltration pattern in CD5+ B-cell chronic lymphocytic leukemia has no independent prognostic significance. Blood, 84, 2084 (abstract).
42. Molica, S. and Alberti, A. (1987). Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Cancer, 60, 2712-2716.
43. Källander, C. F. R., Simonsson, B., Gronowitz, J. S, and Nilsson, K. (1987). Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur. J. Haematol., 38, 331-337.
44. Gronowitz, J. S., Hagberg, H., Kallander, C. F. R. and Simonsson, B. (1983). The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Brit. J. Cancer, 47, 487-495.
45. Hagberg, H., Glimelius, B., Gronowitz, J. S., Killander, A., Kallander, C. F. R. and Schröder, T. (1984). Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis. Scand. J. Haematol., 33, 59-67.
46. Martinsson, U., Glimelius, B., Hagberg, H. and Sundstrom, C. (1989). Primarily asymptomatic low-grade non-Hodgkin's lymphomas: prediction of symptom-free survival and total survival, Eur. J. Haematol., 43, 332-338.
47. Hallek, M., Wanders, L., Ostwald, M., Busch, R., Senekowitsch, R., Stern, S., Schick, H.-D., Kuhn-Hallek, I and Emmerich, B. (1996). Serum β2-microglobulin and thymidine kinase are independent predictors of progressionfree survival in chronic lymphocytic leukemia and immunocytoma. Leukemia & Lymphoma, 22, 439-447.
48. Aguilar-Santelesis, M., Loftenius, A., Ljungh, C., Svenson, S. B., Andersson, B., Mellstadt, H. and Jondal, M. (1992). Serum levels of helper factors (IL-1, IL-1 and IL-6), T-cell products (sCD4 and sCD8), sIL-2R and 2-microglobulin in patients with B-CLL and benign B lymphocytosis. Leukemia Res., 16, 607-613.
49. Yawetz, S., Cumberland, W. G., van der Meyden, M. and Martinez-Maza, O. (1995). Elevated serum levels of soluble CD23 (sCD23) preceed the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. Blood. 85, 1843-1849.
50. French Cooperative Group On Chronic Lymphocytic Leukemia. (1990). Effects of chlorambucil and therapeuticdecision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood, 75, 1414-1421.
51. International Workshop On Chronic Lymphocytic Leukemia (IWCLL). (1989). Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. Ann. Int. Med., 110, 236-238.
52. Keating, M. J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Child, C. C., Freireich, E. J. and McCredie, K. B. (1991). Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol., 9, 44-49.
53. Juliusson, G. and Liliemark, J. (1994). High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients wilh B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol., 11, 679-689.
54. Khouri, I. F., Keating, M. J., Vriesendorp, H. M., Reading, C. L., Przepiorka, D., Huh, Y. O., Andersson, B. S., van Besien, K. W., Mehra, R. C, Giralt, S. A., Ippoliti, C., Marshall, M., Thomas, M. W., O'Brien, S., Robertson, L. E., Deisseroth, A B. and Champlin, R. E. (1994). Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Preliminary results. J. Clin. Oncol., 12, 748-758.